两种广泛研究的GRPR放射性示踪剂放射性标记NeoB与RM2的临床前头对头比较
在临床前模型中头对头比较放射性标记的NeoB与RM2的体外和体内特性,两者在PBS和人血清中稳定性高、GRPR亲和力与特异性高,体内肿瘤摄取无差异;RM2胰腺摄取更低、胰腺半衰期更短、肿瘤/肾比更低,NeoB肿瘤/血比更低且与人肿瘤组织结合更高,作者认为两者体内肿瘤靶向能力相似,需额外研究确定生理器官摄取差异在治疗时是否导致器官吸收剂量相关差异。
要点
- 两者在PBS和人血清中稳定性高,但在小鼠血清中稳定性随时间明显下降。
- 体外研究中[177Lu]Lu-NeoB摄取更高,体内肿瘤摄取两者无差异。
- RM2胰腺摄取更低、胰腺半衰期更短、肿瘤/肾比更低,NeoB肿瘤/血比更低。
核心结论
- 作者认为放射性标记的NeoB与RM2的体内肿瘤靶向能力相似,需额外研究确定胰腺、肾脏和血液等生理器官摄取差异在治疗应用时是否导致器官吸收剂量相关差异。
研究设计与样本
- 临床前研究,比较放射性标记的NeoB与RM2的体外和体内特性。
- 体外测定放射性标记GRPR类似物在磷酸盐缓冲盐水(PBS)、市售小鼠血清和人血清中的稳定性。
- 以人前列腺癌PC-3细胞与[177Lu]Lu-NeoB或[177Lu]Lu-RM2孵育,加或不加递增浓度的未标记NeoB、RM2或Tyr4-蛙皮素(BBN)测定靶点亲和力。
- 细胞与[177Lu]Lu-NeoB或[177Lu]Lu-RM2孵育加或不加Tyr4-BBN测定摄取与特异性。
- 进行体内研究测定生物分布和药代动力学,并研究放射性示踪剂与多种表达GRPR的人癌组织的结合。
主要发现
- 两种放射性示踪剂在PBS和人血清中均显示高稳定性,但在小鼠血清中稳定性随时间明显下降。
- 两种放射性示踪剂均显示高GRPR亲和力和特异性,但体外研究中[177Lu]Lu-NeoB摄取更高。
- 体内研究中两者肿瘤摄取无差异。
- 生理器官摄取最明显的差异见于表达GRPR的胰腺:[177Lu]Lu-RM2的胰腺摄取低于[177Lu]Lu-NeoB,且胰腺半衰期短于[177Lu]Lu-NeoB。
- [177Lu]Lu-RM2的肿瘤/肾比更低,而[177Lu]Lu-NeoB的肿瘤/血比更低;放射自显影研究显示放射性标记NeoB与所有人肿瘤组织的结合更高。
局限性
- 原文结论指出需额外研究确定生理器官摄取差异在治疗应用时是否导致器官吸收剂量相关差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NeoB and RM2 are the most investigated gastrin-releasing peptide receptor (GRPR)-targeting radiotracers in preclinical and clinical studies. Therefore, an extensive side-by-side comparison of the two radiotracers is valuable to demonstrate whether one has advantages over the other. Accordingly, this study aims to compare the in vitro and in vivo characteristics of radiolabeled NeoB and RM2 to guide future clinical studies. METHOD: The stability of the radiolabeled GRPR analogs was determined in phosphate buffered saline (PBS), and commercially available mouse and human serum. Target affinity was determined by incubating human prostate cancer PC-3 cells with [177Lu]Lu-NeoB or [177Lu]Lu-RM2, + / - increasing concentrations of unlabeled NeoB, RM2, or Tyr4-bombesin (BBN). To determine uptake and specificity cells were incubated with [177Lu]Lu-NeoB or [177Lu]Lu-RM2 + / - Tyr4-BBN. Moreover, in vivo studies were performed to determine biodistribution and pharmacokinetics. Finally, radiotracer binding to various GRPR-expressing human cancer tissues was investigated. RESULTS: Both radiotracers demonstrated high stability in PBS and human serum, but stability in mouse serum decreased substantially over time. Moreover, both radiotracers demonstrated high GRPR affinity and specificity, but a higher uptake of [177Lu]Lu-NeoB was observed in in vitro studies. In vivo, no difference in tumor uptake was seen. The most prominent difference in uptake in physiological organs was observed in the GRPR-expressing pancreas; [177Lu]Lu-RM2 had less pancreatic uptake and a shorter pancreatic half-life than [177Lu]Lu-NeoB. Furthermore, [177Lu]Lu-RM2 presented with a lower tumor-to-kidney ratio, while the tumor-to-blood ratio was lower for [177Lu]Lu-NeoB. The autoradiography studies revealed higher binding of radiolabeled NeoB to all human tumor tissues. CONCLUSION: Based on these findings, we conclude that the in vivo tumor-targeting capability of radiolabeled NeoB and RM2 is similar. Additional studies are needed to determine whether the differences observed in physiological organ uptakes, i.e., the pancreas, kidneys, and blood, result in relevant differences in organ absorbed doses when the radiotracers are applied for therapeutic purposes.
引用
- Damiana TST, Paraïso P, de Ridder C, et al. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting. Eur J Nucl Med Mol Imaging. 2023. PMID: 37584725. doi:10.1007/s00259-023-06364-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。